Nabriva appoints Colin Broom as chief executive
Austrian biotech company Nabriva Therapeutics has appointed Colin Broom as chief executive. The company focuses on developing pleuromutilins, a new class of antibiotics for the reatment of serious infections caused by resistant gram-positive and gram-negative pathogens.
Dr Broom has recently served as chief scientific officer at ViroPharma, which was acquired by Shire for $4.2 billion in January 2014. He has also held senior positions at Amgen, Sanofi and GlaxoSmithKline.
The current chief executive Ralf Schmid will move to the role of chief operating officer and chief financial officer. In the same announcement, the company said it would be establishing a US subsidiary, based in Philadelphia, which will be home to the clinical development team, while all other operations will remain in Vienna.
The company plans to take its lead product, lefamulin, into late stage development in community-acquired bacterial pneumonia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze